Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. grew its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,557,479 shares of the company’s stock after purchasing an additional 168,205 shares during the period. Amova Asset Management Americas Inc. owned approximately 2.03% of Nurix Therapeutics worth $14,391,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. increased its position in Nurix Therapeutics by 11.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after acquiring an additional 165,841 shares during the period. Geode Capital Management LLC grew its stake in shares of Nurix Therapeutics by 9.1% in the second quarter. Geode Capital Management LLC now owns 1,881,960 shares of the company’s stock worth $21,437,000 after purchasing an additional 157,592 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Nurix Therapeutics by 19.4% during the second quarter. Affinity Asset Advisors LLC now owns 967,620 shares of the company’s stock valued at $11,021,000 after purchasing an additional 156,951 shares during the period. Bollard Group LLC bought a new stake in shares of Nurix Therapeutics during the second quarter valued at about $1,398,000. Finally, Nikko Asset Management Americas Inc. lifted its holdings in Nurix Therapeutics by 83.8% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock worth $15,796,000 after purchasing an additional 633,304 shares during the period.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NRIX. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a research note on Thursday, January 29th. Royal Bank Of Canada upped their target price on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Truist Financial began coverage on Nurix Therapeutics in a research note on Monday, November 24th. They issued a “buy” rating and a $30.00 price objective on the stock. HC Wainwright raised their target price on Nurix Therapeutics from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Finally, Morgan Stanley set a $36.00 price target on shares of Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Nurix Therapeutics Trading Up 2.8%

Shares of NRIX stock opened at $16.26 on Thursday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -5.35 and a beta of 1.96. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $22.50. The stock’s fifty day simple moving average is $17.45 and its 200-day simple moving average is $14.17.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%.The firm had revenue of $13.58 million during the quarter, compared to analyst estimates of $13.41 million. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the business’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $81,257.00. Following the transaction, the insider owned 83,672 shares in the company, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.40% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.